Thin
Direct factory supply from our Hangzhou multi-ton synthesis base. High-purity APIs featuring batch-specific HPLC purity profiles, MS identity confirmation, and comprehensive impurity fingerprints.
Addressing global pharmaceutical supply security, complex impurity profiles, and cost compression across multi-market commercial generic entries.
With major GLP-1, gastrointestinal, and oncological peptide patents facing expiration across North America, Europe, and Asia-Pacific, innovators and generic pioneers require early chemical development and scalable supply partnerships 3–5 years prior to exclusivity lapse to ensure Day-1 commercial launches.
Regulatory agencies such as the US FDA and EMA mandate exacting thresholds for synthetic peptide impurities, specifically D-enantiomers, truncation fragments, and aggregation complexes. Thinheal utilizes orthogonal high-resolution purification to maintain individual related substances below strict ICH Q3A/B guidelines.
Through high-loading solid supports, solvent recyclability systems, and automated SPPS, we achieve up to 35% higher atom economy and crude purity. This significantly depresses downstream prep-HPLC operational expenditures, translating into sustainable, predictable generic API pricelists for global volume tenders.
Hangzhou Thinheal Pharma-Tech integrates intelligent process automation, green peptide chemistry, and end-to-end trace systems to deliver absolute commercial stability.
Our facility houses 500L, 1000L, and 3000L solid-phase reaction vessels driven by SCADA industrial automation. Real-time temperature control, coupling kinetics monitoring, and precise flow modulation prevent incomplete amino acid extensions in long sequences.
Supply resilience relies on chemical independence. We maintain fully vetted, in-house and domestic strategic reserves for critical Fmoc-protected amino acids, coupling reagents (HATU, HBTU, DIC), pseudoprolines, and specialty side-chain protecting building blocks.
Operated by chemical engineers with nearly 20 years of technical expertise, our commercial infrastructure scales with your clinical or market ramp-up, delivering identical critical quality attributes (CQAs) from initial pilot 100g batches to multi-hundred kilogram commercial releases.
Thinheal’s strategic R&D pipeline embraces next-generation synthetic biology, green manufacturing, and complex lipidation technologies to break traditional production barriers.
Integrating engineered peptide ligases with solid-phase synthesis fragments. This hybrid approach enables the synthesis of 40+ amino acid chains with minimized epimerization and superior overall reaction yield.
Micro-channel TFA cocktail cleavage platforms drastically decrease contact time for labile residues, suppressing methionine oxidation, t-butyl alkylation, and protecting-group reattachment artifacts.
Replacing toxic DMF/NMP with biodegradable, sustainable green alternative solvents (such as Cyrene, 2-MeTHF, and GVL), drastically reducing the E-factor of peptide bulk processing while cutting production costs.
Directed orthogonal protecting strategies (Acm, Trt, Mob) and redox buffer screening enable high-yield, isomer-free synthesis of multi-bridged cyclic generic APIs, including Linaclotide and Plecanatide.
Peptide API pricing depends on chain complexity, modification profiles, salt form displacement, and documentation depth. Below is our scientific pricing and specification matrix.
| Peptide API & CAS No. | Therapeutic Class / Mechanism | Key Synthesis Challenges | Standard Release Purity | Pricelist Drivers & MOQ |
|---|---|---|---|---|
| Semaglutide CAS: 910463-68-2 |
GLP-1 Receptor Agonist (T2D & Obesity) | Lys26 mono-lipidation, Aib substitution, sequence aggregation | ≥ 99.5% (Single max < 0.1%) | Octadecanedioic acid side-chain cost, commercial multi-kg tiers |
| Bremelanotide / PT141 CAS: 189691-06-3 |
Melanocortin Receptor Agonist | Lactam bond macrocyclization, epimerization control | ≥ 99.0% (TFA / Acetate form) | Cyclization efficiency, pilot batches (50g) to 10kg commercial |
| Triptorelin CAS: 57773-63-4 |
GnRH Receptor Agonist (Oncology) | D-Trp6 optical stability, C-terminal Pro-NHEt / amide formation | ≥ 99.0% (Acetate / Pamoate) | Counter-ion type, long-term multi-annual tender contracts |
| Tesamorelin CAS: 218949-48-5 |
GHRH Synthetic Analogue (Lipodystrophy) | 44-amino acid sequence length, N-terminal hexenoyl coupling | ≥ 98.5% (High net content) | Length-dependent synthetic yield, lyophilization batch sizing |
| Teduglutide CAS: 287714-30-1 |
GLP-2 Analogue (Short Bowel Syndrome) | 33-AA sequence, Asp3 isomerization, steric hindered purification | ≥ 98.5% (High biological potency) | High technical barrier, gram-scale R&D to kilogram commercial supply |
| Vasopressin / ADH CAS: 50-57-7 |
Antidiuretic / Vasopressor Agent | Intramolecular Cys-Cys disulfide bridge formation, dimer control | ≥ 99.0% (Sterility & Endotoxin tested) | Oxidation stoichiometry, tight endotoxin specifications (< 5 EU/mg) |
| Eptifibatide CAS: 188627-80-7 |
GP IIb/IIIa Platelet Aggregation Inhibitor | Cyclic heptapeptide with non-canonical mercaptopropionyl residue | ≥ 99.0% | Disulfide regioselectivity, high-volume cardiac emergency market tiers |
* Custom specifications, GMP pilot runs, and specialized counter-ion conversions (Acetate, HCl, TFA-free) provided upon formal quote submission.
Accelerating drug commercialization across all jurisdictions through comprehensive regulatory filing support and regional sales hubs.
We provide comprehensive Module 3 documentation, including Open/Closed DMF parts, CEP packages, and Chinese NMPA filing data. Analytical packages include full method validation (ICH Q2(R1)), stability testing (ICH Q1A(R2)), and elemental impurity assessments (ICH Q3D).
Overcoming time zone barriers and regulatory variations: our localized account desks (Americas & Europe, Russia & CIS, Pan-Asia, Middle East & East Asia) provide responsive technical engagement, commercial quotes, and logistics coordination.
Validated thermal packaging with calibrated temperature data loggers ensures end-to-end (-20°C / 2–8°C) cold-chain custody from our Hangzhou cleanrooms to customer formulation sites globally, eliminating peptide denaturation and peptide deamidation during transit.
Browse our established generic catalog manufactured under strict quality standards. Click any molecule for detailed quotes, CAS verification, and analytical data packages.
Technical, analytical, regulatory, and commercial clarifications to streamline vendor qualification and generic peptide API sourcing.